HeartMate 3 LVAS
Device
Abbott Laboratories
Total Payments
$4.7M
Transactions
493
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $4.7M | 493 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $4.7M | 493 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Multi-Center Study of MagLev Technology in Patients Undergoing MCS Therapy with HeartMate 3 Continued Access Protocol | Abbott Laboratories | $4.7M | 0 |
| Multi-center study of MagLev Technology in Patients Undergoing MCS Therapy with Heartmate 3 | Abbott Laboratories | $63,939 | 0 |
Top Doctors Receiving Payments for HeartMate 3 LVAS
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | New Orleans, LA | $4.7M | 493 |
Ad
Manufacturing Companies
- Abbott Laboratories $4.7M
Product Information
- Type Device
- Total Payments $4.7M
- Total Doctors 0
- Transactions 493
About HeartMate 3 LVAS
HeartMate 3 LVAS is a device associated with $4.7M in payments to 0 healthcare providers, recorded across 493 transactions in the CMS Open Payments database. The primary manufacturer is Abbott Laboratories.
Payment data is available from 2019 to 2019. In 2019, $4.7M was paid across 493 transactions to 0 doctors.
The most common payment nature for HeartMate 3 LVAS is "Unspecified" ($4.7M, 100.0% of total).
HeartMate 3 LVAS is associated with 2 research studies, including "Multi-Center Study of MagLev Technology in Patients Undergoing MCS Therapy with HeartMate 3 Continued Access Protocol" ($4.7M).